Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non‐small cell lung cancer patients

• Published in: Thoracic cancer Vol. 10; no. 7; pp. 1561 - 1566
• Main Authors: Kim, Insu, Eom, Jung Seop, Jo, Eun Jung, Mok.Ki Uk, Jeongha, Lee, Kwangha, Uk Kim, Ki, Park, Hye‐Kyung, Lee, Min Ki, Kim, Mi‐Hyun
• Format: Journal Article
• Language: English
• Published: Melbourne John Wiley & Sons Australia, Ltd 01.07.2019; John Wiley & Sons, Inc; Wiley
• Subjects: Cancer therapies; Deoxyribonucleic acid; DNA; Epidermal growth factor receptor; Genetic aspects; Lung cancer; Lung cancer, Non-small cell; Lung cancer, Small cell; Medical prognosis; Medical research; Medicine, Experimental; Metastasis; Methods; molecular targeted therapy; Mutation; Nervous system; Nucleic acids; Original; Patients; peptide nucleic acid; Peptides; Prognosis; Studies; Survival analysis; South Korea; lung cancer; molecular targeted therapy; prognosis; Epidermal growth factor receptor; peptide nucleic acid

Background The presence of EGFR mutation in patients with advanced non‐small cell lung cancer (NSCLC) plays an important role in determining the appropriate treatment, response, and survival. Therefore, this study attempted to predict the prognosis of NSCLC patients using data from quantitative muta...